ReviewCancer medicine2022

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.

Urbano Anido HerranzPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.